As radiopharmaceuticals move into later-stage development, the strength and relevance of Phase 2 and Phase 3 evidence increasingly determine their impact in precision oncology. This session will focus on how well-designed late-stage clinical data can support regulatory approval and clinical adoption – ultimately translating targeted radiation into meaningful patient benefit.